This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (20)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Social Bookmarking   What's this?

Indiana University Medical Center Experience

Engin Y. Yilmaz, MD, PhD; Michael B. Pritz, MD, PhD; Askiel Bruno, MD; Alfredo Lopez-Yunez, MD; José Biller, MD

Arch Neurol. 2001;58:1274-1278.

Background  Moyamoya usually presents with cerebral ischemia in children and intracranial hemorrhage in adults. Treatment remains controversial.

Design and Objective  We reviewed our experience from June 1995 to August 1999 of 20 adult and pediatric angiographically diagnosed patients with moyamoya to report their clinical presentation, radiological findings, management, and clinical outcomes.

Results  The mean age of patients at symptom onset was 17 years (range, 2-54 years). Patients were divided into 2 age groups (group 1, <18 years; group 2, 18 years). There were 13 patients in group 1 and 7 patients in group 2. Ischemic strokes or transient ischemic attacks were the predominant initial presentations in both groups. One patient in group 2 had an intraparenchymal brain hemorrhage. Five patients received medical treatment, and 15 had surgical revascularization. The mean time from symptom onset to surgical procedure was significantly longer for patients in group 1 than for those in group 2 (P = .03). The mean follow-up time was 36 months. One patient in group 1 had an ischemic stroke. There was no difference in stroke recurrence, mortality, or modified Rankin scale score among medically or surgically treated patients.

Conclusions  Moyamoya disease may have a different presentation and more benign natural history in our population than in Asian populations. Our findings emphasize the need to better understand the natural history of patients with moyamoya as well as the clinical benefit of different treatment modalities. Structured multicenter randomized clinical trials are needed to further assess the best treatment modalities for patients with moyamoya in the United States.

From the Department of Neurology (Drs Yilmaz, Bruno, Lopez-Yunez, and Biller), and Section of Neurological Surgery (Dr Pritz), Indiana University School of Medicine, Indianapolis.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2001;58(8):1319-1321.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Moyamoya Disease and Moyamoya Syndrome
Scott and Smith
NEJM 2009;360:1226-1237.
FULL TEXT  

Ischemic Cerebral Infarction in an Infant Following Gonadotropin Treatment for Undescended Testes
Dundar et al.
J Child Neurol 2008;23:1324-1327.
ABSTRACT  

Management of Stroke in Infants and Children: A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young
Roach et al.
Stroke 2008;39:2644-2691.
ABSTRACT | FULL TEXT  

Clinical and Radiological Recurrence After Childhood Arterial Ischemic Stroke
Ganesan et al.
Circulation 2006;114:2170-2177.
ABSTRACT | FULL TEXT  

Clinical Features and Outcome in North American Adults With Moyamoya Phenomenon
Hallemeier et al.
Stroke 2006;37:1490-1496.
ABSTRACT | FULL TEXT